In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Update: Taking Stock of Biogen Idec

Executive Summary

Like the merger that created Biogen Idec, its new collaboration with PDL is an example of how biotechs can combine to help achieve critical mass. But Biogen Idec still has a lot of heavy lifting to do, especially in one key therapeutic area-oncology.
Advertisement

Related Content

Biogen Idec Charts A New Course
Biogen Idec Charts A New Course
Facet Says Yes To Abbott's $720 Million Buyout Offer
Facet Cuts Shareholder Deals To Fight Off Hostile Biogen Bid
Deal Statistics Quarterly, Q3 2005
Biogen Idec: A Sign of Biotech's Maturation
Biogen Idec: A Sign of Biotech's Maturation
Who's Got Game in Antibody Development?
Who's Got Game in Antibody Development?
Biogen Defends its Specialist Market

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002619

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel